Status:
COMPLETED
Binding and Effects of Lu AG06466 in the Brain of Healthy Men
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Healthy Participants
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
This study is being done to learn about the binding of Lu AG06466 and its major breakdown product (Lu AG06988) in the brain of healthy men having received multiple doses of Lu AG06466. As the binding ...
Eligibility Criteria
Inclusion
- The participant has a body mass index (BMI) ≥18 and ≤30 kilograms (kg)/square meter (m\^2) at the screening visit.
- The participant has a weight of ≥60 kg at the screening visit and baseline visit.
- The participant has a waist circumference ≤94 centimeters (cm) at the screening visit.
Exclusion
- The participant has taken disallowed medication \<2 weeks prior to the first dose of study drug or \<5 half-lives prior to the screening visit for any medication taken.
- The participant has received a COVID-19 vaccination within the last 30 days before receiving first dose of study drug.
- The participant has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder.
- Note: Other inclusion and exclusion criteria may apply.
Key Trial Info
Start Date :
January 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 29 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT05219838
Start Date
January 18 2022
End Date
August 29 2022
Last Update
September 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Invicro, LLC
New Haven, Connecticut, United States, 06510